Abbott is marching to the beat of a very profitable drum, driven by cardiac care dominance, nutrition brand power, and ...

Abbott (ABT) closed the most recent trading day at $131.30, moving -0.15% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.67%. Elsewhere, the Dow saw a ...

Abbott Laboratories (NYSE:ABT) made headlines with its commercial development agreement to integrate advanced diabetes management technology with Sequel Med Tech, aiming to improve outcomes for ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” first-quarter 2025 investor ...

These four Dividend Aristocrats have far outperformed the S&P 500 so far this year, but they still offer investors good entry ...

With both MDT & ABT focusing on their core strengths, the stage is set for a compelling comparison. Let's see which stock is ...

Abbott boasts strong profitability, stable margins, and impressive long-term growth, but recent sales have stagnated. Check ...

Medtronic bumped up its dividend payout and unveiled plans to spin off its diabetes business as the medical-device company targeted revenue growth for the new fiscal year of roughly 5%.

Dividend Kings have outperformed the S&P 500 year-to-date, but recent momentum has slowed. Discover the full story here.

Operating margin of Abbott India significantly improved, widened by 434 bps to 26.7% in Q4 FY25 from 22.9% a year ago quarter.

Citing what they call the S&P 500 price-to-earnings mania, Stifel is once again recommending that what it calls “defensive ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” first quarter ...